Staging of liver fibrosis is crucial in the management of patients with chronic liver diseases (CLD) since fibrosis severity influences the prognosis and treatment options. An early diagnosis of cirrhosis is particularly important in patients with compensated CLD, because it triggers screening for portal hypertension and hepatocellular carcinoma. Liver biopsy has been considered the reference technique for staging liver fibrosis, but has well known limitations, including invasiveness and sampling errors, which have led to explore non-invasive surrogates [1].
No takes yet. Share an insight, caveat, or question.
Berzigotti et al. (2013) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: